Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v10-FR | Version v7-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2021-03-09 | 2020-06-18 |
| Drug Identification Number | 02238525 | 02238525 |
| Brand name | HP-PAC | HP-PAC |
| Common or Proper name | AMOXICILLIN, LANSOPRAZOLE, CLARITHROMYCIN | AMOXICILLIN, LANSOPRAZOLE, CLARITHROMYCIN |
| Company Name | TAKEDA PHARMACEUTICALS AMERICA INC | TAKEDA PHARMACEUTICALS AMERICA INC |
| Ingredients | LANSOPRAZOLE AMOXICILLIN CLARITHROMYCIN | LANSOPRAZOLE AMOXICILLIN CLARITHROMYCIN |
| Strength(s) | 30MG 500MG 500MG | 30MG 500MG 500MG |
| Dosage form(s) | KIT CAPSULE TABLET CAPSULE (DELAYED RELEASE) | KIT CAPSULE TABLET CAPSULE (DELAYED RELEASE) |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | HP PAC 7 DAY THERAPY | HP PAC 7 DAY THERAPY |
| ATC code | A02BD | A02BD |
| ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | ||
| Actual discontinuation date | 2021-03-08 | 2020-06-22 |
| Remaining supply date | 2020-06-30 | 2020-06-30 |
| Discontinuation status | Discontinued | To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | Product discontinued for business reason. | |
| Health Canada comments |